BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res. 2012;18:2515-2525. [PMID: 22392911 DOI: 10.1158/1078-0432.ccr-11-2683] [Cited by in Crossref: 139] [Cited by in F6Publishing: 85] [Article Influence: 13.9] [Reference Citation Analysis]
Number Citing Articles
1 Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget 2012;3:1416-27. [PMID: 23232026 DOI: 10.18632/oncotarget.724] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
2 Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) 2015;3:269-76. [PMID: 26337942 DOI: 10.1093/gastro/gov046] [Cited by in Crossref: 19] [Cited by in F6Publishing: 58] [Article Influence: 2.7] [Reference Citation Analysis]
3 Jung J, Seol HS, Chang S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research. Cancer Res Treat. 2018;50:1-10. [PMID: 28903551 DOI: 10.4143/crt.2017.307] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 19.6] [Reference Citation Analysis]
4 Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-6361 [PMID: 27605871 DOI: 10.3748/wjg.v22.i28.6345] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
5 Kim HJ, Lee SY, Oh SC. The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. Front Physiol. 2016;7:168. [PMID: 27242542 DOI: 10.3389/fphys.2016.00168] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) 2014;92:709-22. [PMID: 24811491 DOI: 10.1007/s00109-014-1161-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
7 Flobak Å, Baudot A, Remy E, Thommesen L, Thieffry D, Kuiper M, Lægreid A. Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling. PLoS Comput Biol 2015;11:e1004426. [PMID: 26317215 DOI: 10.1371/journal.pcbi.1004426] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
8 Jones GG, Del Río IB, Sari S, Sekerim A, Young LC, Hartig N, Areso Zubiaur I, El-Bahrawy MA, Hynds RE, Lei W, Molina-Arcas M, Downward J, Rodriguez-Viciana P. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat Commun 2019;10:2532. [PMID: 31182717 DOI: 10.1038/s41467-019-10367-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
9 Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Mol Clin Oncol. 2015;3:1053-1057. [PMID: 26623049 DOI: 10.3892/mco.2015.602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
10 Sebolt-Leopold JS. Development of Preclinical Models to Understand and Treat Colorectal Cancer. Clin Colon Rectal Surg. 2018;31:199-204. [PMID: 29720906 DOI: 10.1055/s-0037-1602240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Tsubaki M, Takeda T, Noguchi M, Jinushi M, Seki S, Morii Y, Shimomura K, Imano M, Satou T, Nishida S. Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells. Cancers (Basel) 2019;11:E1866. [PMID: 31769426 DOI: 10.3390/cancers11121866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 2015;47:250-6. [PMID: 25665005 DOI: 10.1038/ng.3218] [Cited by in Crossref: 277] [Cited by in F6Publishing: 260] [Article Influence: 39.6] [Reference Citation Analysis]
13 Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C. Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. PLoS One 2012;7:e51449. [PMID: 23227266 DOI: 10.1371/journal.pone.0051449] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
14 Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, Ma KW, Xia W, Cheung TT. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics 2018;8:3737-50. [PMID: 30083256 DOI: 10.7150/thno.25487] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
15 Tosi D, Pérez-Gracia E, Atis S, Vié N, Combès E, Gabanou M, Larbouret C, Jarlier M, Mollevi C, Torro A, Del Rio M, Martineau P, Gongora C. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer 2018;18:812. [PMID: 30103709 DOI: 10.1186/s12885-018-4712-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Guo S, Jiang X, Mao B, Li QX. The design, analysis and application of mouse clinical trials in oncology drug development. BMC Cancer 2019;19:718. [PMID: 31331301 DOI: 10.1186/s12885-019-5907-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
17 Ichimanda M, Hijiya N, Tsukamoto Y, Uchida T, Nakada C, Akagi T, Etoh T, Iha H, Inomata M, Takekawa M, Moriyama M. Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas. Cancer Sci 2018;109:250-8. [PMID: 29150975 DOI: 10.1111/cas.13444] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
18 Seol YM, Kwon CH, Lee SJ, Lee SJ, Choi Y, Choi YJ, Kim H, Park DY. A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy. Transl Oncol 2019;12:301-7. [PMID: 30448735 DOI: 10.1016/j.tranon.2018.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Brown KM, Xue A, Mittal A, Samra JS, Smith R, Hugh TJ. Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review. Oncotarget 2016;7:66212-25. [PMID: 27517155 DOI: 10.18632/oncotarget.11184] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
20 Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, Lin CC, Hwang WL, Tzeng CH, Li AF, Yen CC, Teng HW. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J Cancer Res Clin Oncol 2014;140:561-71. [PMID: 24493623 DOI: 10.1007/s00432-014-1596-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
21 Rosato RR, Dávila-González D, Choi DS, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Breast Cancer Res 2018;20:108. [PMID: 30185216 DOI: 10.1186/s13058-018-1037-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
22 Zheng GW, Tang MM, Shu CY, Xin WX, Zhang YH, Chi BB, Shi MR, Guo X, Zhang ZZ, Lian XY. A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. Cell Death Dis 2020;11:982. [PMID: 33191401 DOI: 10.1038/s41419-020-03191-5] [Reference Citation Analysis]
23 Li Q, Dai W, Liu J, Li YX, Li YY. DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models. J Transl Med 2019;17:39. [PMID: 30696439 DOI: 10.1186/s12967-019-1785-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yagishita S, Kato K, Takahashi M, Imai T, Yatabe Y, Kuwata T, Suzuki M, Ochiai A, Ohtsu A, Shimada K, Nishida T, Hamada A, Mano H. Characterization of the large-scale Japanese patient-derived xenograft (J-PDX) library. Cancer Sci 2021;112:2454-66. [PMID: 33759313 DOI: 10.1111/cas.14899] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: Past, present and future perspectives. World J Gastroenterol 2020; 26(13): 1394-1426 [PMID: 32308343 DOI: 10.3748/wjg.v26.i13.1394] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
26 Kirouac DC, Schaefer G, Chan J, Merchant M, Orr C, Huang SA, Moffat J, Liu L, Gadkar K, Ramanujan S. Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model. NPJ Syst Biol Appl 2017;3:14. [PMID: 28649441 DOI: 10.1038/s41540-017-0016-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
27 van 't Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, Bolhuis K, van Waesberghe JTM, Swijnenburg RJ, van den Broek D, Velculescu VE, Kazemier G, Punt CJA, Meijer GA, Fijneman RJA. KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. JCO Precis Oncol 2021;5:PO. [PMID: 34820593 DOI: 10.1200/PO.21.00223] [Reference Citation Analysis]
28 Harris FR, Zhang P, Yang L, Hou X, Leventakos K, Weroha SJ, Vasmatzis G, Kovtun IV. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. Mol Oncol 2019;13:132-52. [PMID: 30499260 DOI: 10.1002/1878-0261.12414] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
29 Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R, Weichert JP, Halberg RB. mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. PLoS One 2013;8:e60709. [PMID: 23593290 DOI: 10.1371/journal.pone.0060709] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
30 Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M, Nishida N, Uemura M, Hata T, Takemasa I. Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. Mol Ther Nucleic Acids. 2015;4:e231. [PMID: 25756961 DOI: 10.1038/mtna.2015.5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
31 Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014;4:998-1013. [PMID: 25185190 DOI: 10.1158/2159-8290.CD-14-0001] [Cited by in Crossref: 863] [Cited by in F6Publishing: 552] [Article Influence: 107.9] [Reference Citation Analysis]
32 El-Daly SM, Abba ML, Patil N, Allgayer H. miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. Sci Rep 2016;6:24720. [PMID: 27095166 DOI: 10.1038/srep24720] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
33 Novo SM, Wedge SR, Stark LA. Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. Sci Rep 2017;7:12020. [PMID: 28931905 DOI: 10.1038/s41598-017-12222-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
34 Wang C, Fakih M. Targeting KRAS in Colorectal Cancer. Curr Oncol Rep 2021;23:28. [PMID: 33582927 DOI: 10.1007/s11912-021-01022-0] [Reference Citation Analysis]
35 Na D, Moon HG. Patient-Derived Xenograft Models in Breast Cancer Research. Adv Exp Med Biol 2021;1187:283-301. [PMID: 33983584 DOI: 10.1007/978-981-32-9620-6_14] [Reference Citation Analysis]
36 Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PLoS One 2018;13:e0200836. [PMID: 30118499 DOI: 10.1371/journal.pone.0200836] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
37 Ohta S, Tago K, Kuchimaru T, Funakoshi-Tago M, Horie H, Aoki-Ohmura C, Matsugi J, Yanagisawa K. The role of MerTK in promoting cell migration is enhanced by the oncogenic Ras/IL-33 signaling axis. FEBS J 2021. [PMID: 34743410 DOI: 10.1111/febs.16271] [Reference Citation Analysis]
38 Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 2017;28:2595-605. [PMID: 28945830 DOI: 10.1093/annonc/mdx416] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 28.0] [Reference Citation Analysis]
39 Zhang Z, Li Z, Li Y, Zang A. MicroRNA and signaling pathways in gastric cancer. Cancer Gene Ther 2014;21:305-16. [PMID: 25060632 DOI: 10.1038/cgt.2014.37] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
40 De Angelis ML, Francescangeli F, Zeuner A, Baiocchi M. Colorectal Cancer Stem Cells: An Overview of Evolving Methods and Concepts. Cancers (Basel) 2021;13:5910. [PMID: 34885020 DOI: 10.3390/cancers13235910] [Reference Citation Analysis]
41 Zhou Y, Hu HY, Meng W, Jiang L, Zhang X, Sha JJ, Lu Z, Yao Y. MEK inhibitor effective against proliferation in breast cancer cell. Tumour Biol 2014;35:9269-79. [PMID: 24938872 DOI: 10.1007/s13277-014-1901-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
42 Toulany M, Iida M, Keinath S, Iyi FF, Mueck K, Fehrenbacher B, Mansour WY, Schaller M, Wheeler DL, Rodemann HP. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Oncotarget 2016;7:43746-61. [PMID: 27248324 DOI: 10.18632/oncotarget.9670] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
43 Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer. 2016;138:195-205. [PMID: 26152787 DOI: 10.1002/ijc.29676] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
44 Klinghammer K, Politz O, Eder T, Otto R, Raguse JD, Albers A, Kaufmann A, Tinhofer I, Hoffmann J, Keller U, Keilholz U. Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. Oncotarget 2020;11:3688-97. [PMID: 33110476 DOI: 10.18632/oncotarget.27763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
45 Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 2017;17:254-68. [PMID: 28104906 DOI: 10.1038/nrc.2016.140] [Cited by in Crossref: 321] [Cited by in F6Publishing: 287] [Article Influence: 64.2] [Reference Citation Analysis]
46 Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, Carlson BL, Ma DJ, Sarkar G, Evers L, Decker PA, Yan H, Dhruv HD, Berens ME, Wang Q, Marin BM, Klee EW, Califano A, LaChance DH, Eckel-Passow JE, Verhaak RG, Sulman EP, Burns TC, Meyer FB, O'Neill BP, Tran NL, Giannini C, Jenkins RB, Parney IF, Sarkaria JN. Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clin Cancer Res 2020;26:1094-104. [PMID: 31852831 DOI: 10.1158/1078-0432.CCR-19-0909] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 12.7] [Reference Citation Analysis]
47 Tabchy A, Eltonsy N, Housman DE, Mills GB. Systematic identification of combinatorial drivers and targets in cancer cell lines. PLoS One 2013;8:e60339. [PMID: 23577104 DOI: 10.1371/journal.pone.0060339] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
48 van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. Curr Colorectal Cancer Rep 2015;11:335-44. [PMID: 26617477 DOI: 10.1007/s11888-015-0288-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
49 Krasnov GS, Dmitriev AA, Melnikova NV, Zaretsky AR, Nasedkina TV, Zasedatelev AS, Senchenko VN, Kudryavtseva AV. CrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanisms. Nucleic Acids Res 2016;44:e62. [PMID: 26773058 DOI: 10.1093/nar/gkv1478] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
50 D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br J Cancer 2014;110:2887-95. [PMID: 24823695 DOI: 10.1038/bjc.2014.241] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
51 Prahallad A, Bernards R. Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene 2016;35:1073-9. [PMID: 25982281 DOI: 10.1038/onc.2015.151] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
52 Shiovitz S, Grady WM. Molecular markers predictive of chemotherapy response in colorectal cancer. Curr Gastroenterol Rep 2015;17:431. [PMID: 25663616 DOI: 10.1007/s11894-015-0431-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
53 Temraz S, Mukherji D, Shamseddine A. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Int J Mol Sci. 2015;16:22976-22988. [PMID: 26404261 DOI: 10.3390/ijms160922976] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 10.1] [Reference Citation Analysis]
54 Šuštić T, van Wageningen S, Bosdriesz E, Reid RJD, Dittmar J, Lieftink C, Beijersbergen RL, Wessels LFA, Rothstein R, Bernards R. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers. Genome Med 2018;10:90. [PMID: 30482246 DOI: 10.1186/s13073-018-0600-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
55 Lau KS, Schrier SB, Gierut J, Lyons J, Lauffenburger DA, Haigis KM. Network analysis of differential Ras isoform mutation effects on intestinal epithelial responses to TNF-α. Integr Biol (Camb) 2013;5:1355-65. [PMID: 24084984 DOI: 10.1039/c3ib40062j] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
56 Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658-673. [PMID: 23729478 DOI: 10.1158/2159-8290.cd-12-0558] [Cited by in Crossref: 421] [Cited by in F6Publishing: 249] [Article Influence: 46.8] [Reference Citation Analysis]
57 Bettoun A, Joffre C, Zago G, Surdez D, Vallerand D, Gundogdu R, Sharif AA, Gomez M, Cascone I, Meunier B, White MA, Codogno P, Parrini MC, Camonis JH, Hergovich A. Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation. Oncotarget 2016;7:44142-60. [PMID: 27283898 DOI: 10.18632/oncotarget.9875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
58 García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res 2015;21:5499-510. [PMID: 26272063 DOI: 10.1158/1078-0432.CCR-14-3091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
59 Cash H, Shah S, Moore E, Caruso A, Uppaluri R, Van Waes C, Allen C. mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. Oncotarget 2015;6:36400-17. [PMID: 26506415 DOI: 10.18632/oncotarget.5063] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
60 Šuštić T, Bosdriesz E, van Wageningen S, Wessels LFA, Bernards R. RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer. Transl Oncol 2020;13:201-11. [PMID: 31865182 DOI: 10.1016/j.tranon.2019.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Rampioni Vinciguerra GL, Dall'Acqua A, Segatto I, Mattevi MC, Russo F, Favero A, Cirombella R, Mungo G, Viotto D, Karimbayli J, Pesce M, Vecchione A, Belletti B, Baldassarre G. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer. Cell Death Dis 2021;12:951. [PMID: 34654798 DOI: 10.1038/s41419-021-04241-2] [Reference Citation Analysis]
62 Williams JA. Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field. J Clin Med 2018;7:E41. [PMID: 29498669 DOI: 10.3390/jcm7030041] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]
63 Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS, Rueda OM, Bosdriesz E, Caldas C, Wessels LFA, Bernards R. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res 2018;28:719-29. [PMID: 29795445 DOI: 10.1038/s41422-018-0044-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 12.0] [Reference Citation Analysis]
64 Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget 2016;7:39595-608. [PMID: 27167191 DOI: 10.18632/oncotarget.9153] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 14.3] [Reference Citation Analysis]
65 Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol 2013;4:308-18. [PMID: 23997942 DOI: 10.3978/j.issn.2078-6891.2013.029] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
66 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
67 Rizzo G, Bertotti A, Leto SM, Vetrano S. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. J Exp Clin Cancer Res 2021;40:178. [PMID: 34074330 DOI: 10.1186/s13046-021-01970-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Cheung PF, Yip CW, Ng LW, Lo KW, Chow C, Chan KF, Cheung TT, Cheung ST. Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line. Cancer Cell Int 2016;16:41. [PMID: 27279800 DOI: 10.1186/s12935-016-0322-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
69 Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers (Basel) 2019;11:E1321. [PMID: 31500168 DOI: 10.3390/cancers11091321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
70 Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med 2016;14:119. [PMID: 27149858 DOI: 10.1186/s12967-016-0872-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
71 Kuger S, Flentje M, Djuzenova CS. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Radiat Oncol. 2015;10:214. [PMID: 26498922 DOI: 10.1186/s13014-015-0514-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
72 Hashemzadeh K, Jokar MH, Sedighi S, Moradzadeh M. Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer. Middle East J Dig Dis 2019;11:5-16. [PMID: 31049177 DOI: 10.15171/mejdd.2018.122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Kwong LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res 2013;19:5310-9. [PMID: 24089444 DOI: 10.1158/1078-0432.CCR-13-0142] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
74 Moiola CP, Lopez-Gil C, Cabrera S, Garcia A, Van Nyen T, Annibali D, Fonnes T, Vidal A, Villanueva A, Matias-Guiu X, Krakstad C, Amant F, Gil-Moreno A, Colas E. Patient-Derived Xenograft Models for Endometrial Cancer Research. Int J Mol Sci 2018;19:E2431. [PMID: 30126113 DOI: 10.3390/ijms19082431] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
75 Rittler D, Molnár E, Baranyi M, Garay T, Hegedűs L, Aigner C, Tóvári J, Tímár J, Hegedűs B. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations. Int J Mol Sci 2020;21:E7649. [PMID: 33081092 DOI: 10.3390/ijms21207649] [Reference Citation Analysis]
76 Roper J, Sinnamon MJ, Coffee EM, Belmont P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz ÖH, Bronson RT, Martin ES, Tsichlis PN, Hung KE. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett 2014;347:204-11. [PMID: 24576621 DOI: 10.1016/j.canlet.2014.02.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
77 Clarke PA, Roe T, Swabey K, Hobbs SM, McAndrew C, Tomlin K, Westwood I, Burke R, van Montfort R, Workman P. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. Oncogene 2019;38:5076-90. [PMID: 30905967 DOI: 10.1038/s41388-019-0780-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
78 Bailey ST, Zhou B, Damrauer JS, Krishnan B, Wilson HL, Smith AM, Li M, Yeh JJ, Kim WY. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PLoS One 2014;9:e104413. [PMID: 25180793 DOI: 10.1371/journal.pone.0104413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
79 Zhou Y, Lin S, Tseng KF, Han K, Wang Y, Gan ZH, Min DL, Hu HY. Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells. BMC Cancer 2016;16:818. [PMID: 27769200 DOI: 10.1186/s12885-016-2773-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
80 Gong J, Chen Y, Yang L, Pillai R, Shirasawa S, Fakih M. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. Anticancer Res 2017;37:2831-8. [PMID: 28551618 DOI: 10.21873/anticanres.11634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
81 Park SH, Jo MJ, Kim BR, Jeong YA, Na YJ, Kim JL, Jeong S, Yun HK, Kim DY, Kim BG, Kang SH, Oh SC, Lee DH. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics 2019;9:2235-51. [PMID: 31149041 DOI: 10.7150/thno.30678] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
82 Broyde J, Simpson DR, Murray D, Paull EO, Chu BW, Tagore S, Jones SJ, Griffin AT, Giorgi FM, Lachmann A, Jackson P, Sweet-Cordero EA, Honig B, Califano A. Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses. Nat Biotechnol 2021;39:215-24. [PMID: 32929263 DOI: 10.1038/s41587-020-0652-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F, Comoglio PM. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. Mol Oncol 2015;9:1760-72. [PMID: 26119717 DOI: 10.1016/j.molonc.2015.05.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
84 Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, Jobard A, Alt M, Ricci F, Loirat D, Sablin MP, Bretagne M, Saint-Ghislain M, Hescot S, Gonçalves A, Tredan O, Dubot C, Gavoille C, Delord JP, Campone M, Isambert N, Belin L, Bieche I, Kamal M, Le Tourneau C. Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. JCO Precis Oncol 2018;2:PO. [PMID: 32914004 DOI: 10.1200/PO.18.00048] [Reference Citation Analysis]
85 Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, Pook D, Pezaro CJ, Sandhu S, Keerthikumar S, Quezada Urban R, Papargiris M, Kraska J, Madsen HB, Wang H, Richards MG, Niranjan B, O'Dea S, Teng L, Wheelahan W, Li Z, Choo N, Ouyang JF, Thorne H, Devereux L, Hicks RJ, Sengupta S, Harewood L, Iddawala M, Azad AA, Goad J, Grummet J, Kourambas J, Kwan EM, Moon D, Murphy DG, Pedersen J, Clouston D, Norden S, Ryan A, Furic L, Goode DL, Frydenberg M, Lawrence MG, Taylor RA. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat Commun 2021;12:5049. [PMID: 34413304 DOI: 10.1038/s41467-021-25175-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
86 Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PLoS One 2014;9:e113037. [PMID: 25401499 DOI: 10.1371/journal.pone.0113037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
87 Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. Clin Cancer Res 2016;22:405-14. [PMID: 26369631 DOI: 10.1158/1078-0432.CCR-15-0829] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
88 Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Mol Cancer Ther 2016;15:1656-68. [PMID: 27196759 DOI: 10.1158/1535-7163.MCT-15-0857] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]